Chimeric antigen receptor (CAR) modified T-cell therapy has revolu-tionized the treatment of relapsed and refractory lymphoid neoplasms. Despite impressive responses, malignant cells might evade CAR T-cells due to their ability to lose the CD19 antigen. Our novel strategy of multi-targeted CAR T-cells may help us overcome this obstacle.